Lisa Roth, MD, Weill Cornell Medicine, New York, NY, discusses a multicenter retrospective study of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who received brentuximab vedotin (BV) as maintenance therapy following autologous stem cell transplantation (autoSCT). Dr Roth shares that the treatment was well tolerated and safe, suggesting that this agent may be a promising option for pediatric patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.